X4 Pharmaceuticals, Inc. (XFOR)

NASDAQ: XFOR · IEX Real-Time Price · USD
1.410
-0.040 (-2.76%)
At close: Mar 27, 2024, 4:00 PM
1.400
-0.010 (-0.71%)
Pre-market: Mar 28, 2024, 4:32 AM EDT

Company Description

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.

Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.

The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases.

It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications.

The company is headquartered in Boston, Massachusetts.

X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals logo
Country United States
Founded 2014
Industry Biotechnology
Sector Healthcare
Employees 93
CEO Dr. Paula Ragan Ph.D.

Contact Details

Address:
61 North Beacon Street, 4th Floor
Boston, Massachusetts 02134
United States
Phone 857-529-8300
Website x4pharma.com

Stock Details

Ticker Symbol XFOR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001501697
CUSIP Number 98420X103
ISIN Number US98420X1037
Employer ID 27-3181608
SIC Code 2836

Key Executives

Name Position
Dr. Paula Ragan Ph.D. Chief Executive Officer, President and Director
Adam S. Mostafa Chief Financial Officer, Treasurer and Corporate Secretary
Dr. Mary DiBiase Ph.D. Chief Operating Officer
Dr. Richard Peters M.D., Ph.D. Founder
Dr. Renato T. Skerlj Ph.D. Founder
Dr. Keith T. Flaherty M.D. Founder and Member of Corporate Advisory Board
Dr. Arthur Taveras Ph.D. Chief Scientific Officer
Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. Vice President of Investor Relations and Corporate Communications
Dr. Robert David Arbeit Senior Vice President of Clinical Development and Translational Research
Mark Baldry M.B.A. Chief Commercial Officer

Latest SEC Filings

Date Type Title
Mar 21, 2024 10-K Annual Report
Mar 21, 2024 8-K Current Report
Mar 11, 2024 144 Filing
Mar 11, 2024 144 Filing
Mar 11, 2024 144 Filing
Mar 11, 2024 144 Filing
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals